Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of LncRNA EPB41L4A-AS1 as marker for diagnosing and treating acute myelogenous leukemia

A technology for acute myeloid and leukemia, applied in the fields of molecular biology and biomedicine, can solve the problems of interfering with hematopoietic stem cells-microenvironment homeostasis

Inactive Publication Date: 2020-07-28
长沙医路相守生物科技有限公司
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But in the malignant setting, acute myeloid leukemia cells infiltrate the bone marrow, disturbing normal hematopoietic stem cell-microenvironment homeostasis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of LncRNA EPB41L4A-AS1 as marker for diagnosing and treating acute myelogenous leukemia
  • Application of LncRNA EPB41L4A-AS1 as marker for diagnosing and treating acute myelogenous leukemia
  • Application of LncRNA EPB41L4A-AS1 as marker for diagnosing and treating acute myelogenous leukemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0024] The preferred embodiments of the present invention will be described in detail below in conjunction with the accompanying drawings, so that the advantages and features of the present invention can be more easily understood by those skilled in the art, so that the protection scope of the present invention can be more clearly defined. The experimental methods not described in detail in the examples are usually carried out in accordance with conventional operations in the technical field or in accordance with the conditions recommended by the manufacturer. The reagents and drugs involved in the examples, unless otherwise specified, are all common commercial products.

[0025] After extensive and in-depth research, the present invention detects the expression level of long-chain non-coding RNA in AML tissue through bioinformatics technology and molecular biology technology, and finds long-chain non-coding RNA fragments with obvious expression differences, and explores its relat...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a long non-coding RNA for treating acute myelogenous leukemia. Particularly, the long non-coding RNA is LncRNA EPB41L4A-AS1. The invention discloses an application of the LncRNA EPB41L4A-AS1 to preparation of a product for treating the acute myelogenous leukemia. The invention simultaneously discloses a pharmaceutical composition for treating the acute myelogenous leukemiaand a kit for evaluating the LncRNA EPB41L4A-AS1. The pharmaceutical composition disclosed by the invention has a relatively good inhibitory effect on the acute myelogenous leukemia, and has importantreference significance and practical significance in treatment of the acute myelogenous leukemia. The kit disclosed by the invention can serve as one of methods for evaluating the expression level ofthe LncRNA EPB41L4A-AS1 and has relatively good measurement and guide effects on the LncRNA EPB41L4A-AS1 when used as the pharmaceutical composition.

Description

Technical field [0001] The present invention relates to a long-chain non-coding RNA related to acute myeloid leukemia and its application in acute myeloid leukemia. The long-chain non-coding RNA is LncRNA EPB41L4A-AS1. It belongs to the field of biomedicine, specifically the field of molecular biology technology. Background technique [0002] Acute myeloid leukemia (AML) is a malignant tumor caused by immature myeloid hematopoietic cells in the bone marrow. This is a highly heterogeneous hematological malignancy. Its incidence increases with people’s age, reaching a peak at the age of 65. According to the National Institutes of Health (NIH) statistics, every 100,000 people per year Among them, 2.4 people were diagnosed with acute myeloid leukemia, and its mortality accounted for about 1.2% of the deaths due to cancer. Acute myeloid leukemia is also an aggressive hematological tumor, with multiple genotypes, phenotypes, epigenetic characteristics and net response to anti-leukemi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/113C12Q1/6886A61K31/7105A61P35/02
CPCA61K31/7105A61P35/02C12N15/113C12Q1/6886C12Q2600/158C12Q2600/178
Inventor 刘群丽吕昕童铁
Owner 长沙医路相守生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com